D. Gail McCarver, MD - Publications
Original Observations in Refereed Journals
1. Ward WA, May DG, Branch RA: Quantitative determination of carbaryl and carbaryl metabolites by reverse-phase high performance liquid chromatography. J Chromatogr, 388:462-467, 1987.
2. May DG, Stratton CW, Denney WD, Watts FL, Bernard GR, Branch RA: Vancomycin entry into lung lymph in sheep. Antimicrob Agents Chemother, 31:1689-1691, 1987.
3. Ward SA, May DG, Heath AJ, Branch RA: Cimetidine induced inhibition of carbaryl metabolism. Clin Toxicol, 26:269-281, 1988.
4. May DG, Black CM, Olsen N, Csuka ME, Tanner B, Bellino L, Porter J, Wilkinson GR, Branch RA: Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquine and mephenytoin. Clin Pharmacol Ther, 48:286-295, 1990.
5. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA: The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin Pharmacol Ther, 48:619-627, 1990.
6. May DG, Naukam RJ, Kambam JR, Heath AJ, Branch RA: Cimetidine-carbaryl interaction in humans: evidence for an active metabolite of carbaryl. J Pharmacol Exp Ther, 262(3):1057-1061, 1992.
7. May DG, Arns PA, Richards WO, Porter J, Ryder D, Fleming CM, Wilkinson GR, Branch RA: The disposition of dapsone in cirrhosis. Clin Pharmacol Ther, 51:689-700, 1992.
8. Black C, May DG, Csuka ME, Lupoli S, Wilkinson GR, Branch RA: Activity of oxidative routes of metabolism of debrisoquine, mephenytoin and dapsone is unrelated to pathogenesis of vinyl chloride-induced disease. Clin Pharmacol Ther, 52:659-667, 1992.
9. May DG, Porter J, Wilkinson GR, Branch RA: Frequency distribution of dapsone Bhydroxylase: a putative probe for P4503A4 activity in a white population. Clin Pharmacol Ther, 55:492-500, 1994.
10. McCarver-May DG, Kang J, Aouthmany A, Elton RE, Mowery JL, Slovis TL, Kauffman R: Comparison of chloral hydrate and midazolam for sedation of neonates for neuroimaging studies. J Pediatr, 128(4):573-576, 1996.
11. McCarver-May DG, Durisin L: Human hepatic alcohol dehydrogenase (ADH) and human erythrocyte catalase do not metabolize the cytochrome P4502E1 substrate, chlorzoxazone. Alcohol Clin Exp Res, 20(3):533-537, 1996.
12. Seagull FN, Mowery JL, Simpson PM, Robinson TR, Martier SS, Sokol RJ, McCarver-May DG: Maternal assessment of infant development: associations with alcohol and drug use in pregnancy. Clin Pediatr, 35:621-628, 1996.
13. McCarver-May DG, Durisin L: An accurate, automated simultaneous gas chromatographic head space measurement of whole blood ethanol and acetaldehyde for human in vivo studies. J Anal Toxicol, 21:134-141, 1997.
14. *Rasheed A, Hines RN, McCarver-May DG: Variation in induction of human placental CYP2E1: Possible role in susceptibility to fetal alcohol syndrome? Tox Appl Pharmacol, 144:396-400, 1997.
15. *McCarver DG, Thomasson H, Martier SS, Sokol R, Li T-K: Presence of the ADH2*3 gene protects against neurobehavioral deficits in offspring exposed to intrauterine ethanol. J Pharmacol Exp Ther, 283; 1095-1101, 1997.
16. Donnelly FM, Mowery JL, McCarver DG: Knowledge and misconceptions in inner city African American mothers regarding alcohol and drug use. Am J Drug Alcohol Abuse, 24(4):675-683, 1998.
17. *McCarver DG, Byun R, Hines RN, Hichme M, Wegenek: A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake, Toxicol Appl Pharmacol, 152:276-281, 1998.
18. Adedoyin A, Branch RA, Bluhm RE, McCarver DG: Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 65:598-605, June 1999.
19. Whetstine JR, Yueh MF, Hopp KA, McCarver DG, Williams DE, Park CS, Kang JH, Cha YN, Dolphin CT, Shephard EA, Phillips IR, and Hines RN: Ethnic differences in human flavin-containing monooxygenase 2(FMO2) polymorphisms: Detection of expressed protein in African Americans. Toxicol Appl Pharmacol, in press 2000.
20. McCarver DG: ADH2 and CYP2E1 genetic polymorphisms: Risk factors for alcohol-related birth defects, Drug Metab Dispos, in press 2000.
21. McCarver DG, Elton RE, Mowery JL, Durisin L: Chloral hydrate metabolism in infants and adults: Explanation of increased cancer risk in children following sedative exposure? In preparation, 2000.
22. McCarver DG, Thomasson HR, Martier SS, Sokol R, Li T-K: Impact of ADH genotype and ethanol intake on alcohol metabolism in African American women. In preparation, 2000.
23. Ealovega M, Byun R, Hichme M, McCarver DG: CYP2E1 metabolic ability in African American women. In preparation, 2000.
Review Articles:
1. Ahmed MEK, May DG, Branch RA: Cefotetan (Cefotan): A new cephalosporin. Rational Drug Therapy, 20:1-5, 1986.
2. May DG, Branch RA: Imipenem: Do we need it? Medical Sciences, 31:289-291, 1988.
3. May DG, Kauffman RE: Neonatal Pharmacology. Current Opinion in Pediatrics, 4(2):299-304, 1992.
4. May DG: Genetic differences in drug disposition. J Clin Pharmacol, 34:881-897, 1994.
5. Miller ST, McCarver DG, Bell DA, Eaton DL, Goldstein JA: Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol, 40:1-14, 1997.
Letters and Commentaries:
1. Berlin CM, Gorman RL, May DG, Notterman DA, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Reappraisal of lytic cocktail/Demerol, Phenergan, and Thorazine (DPT) for the sedation of children. Pediatrics, 95(4): 598-602, 1995.
2. Berlin CM, Gorman RL, May DG, Notterman DA, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Treatment guidelines for lead exposure in children. Pediatrics 96(1):155-160, 1995.
3. Berlin CM, May DG, Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 96(3):538-540, 1995.
4. Berlin CM, May DG, Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. Pediatrics 98(1):143-145, 1996.
5. McCarver-May DG: Reply to AChloral hydrate versus midazolam sedation for neuroimaging studies@. J Pediatr 129(6):945, 1996.
6. Berlin CM, McCarver-May DG, Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT, Frader JE, Crain LS, Moseley KL, Nelson RM, Porter IH, Vizcarrondo FE (American Academy of Pediatrics Committee on Drugs and Committee on Bioethics): Considerations related to the use of recombinant human growth hormone in children. Pediatrics 99(1):122-129, 1997.
7. Berlin CM, McCarver DG, Notterman DA, Ward RM, Weisman DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): AInactive@ ingredients in pharmaceutical products: update (subject review). Pediatrics 99(2):268-278, 1997.
8. Berlin CM, McCarver-May DG, Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Use of codeine- and dextromethorphan-containing cough remedies in children. Pediatrics 99(6):918-920, 1997.
9. Berlin CM, McCarver-May DG, Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Alternative routes of drug administration - advantages and disadvantages. Pediatrics 100(1):143-52, 1997.
10. Berlin CM, May DG (lead author), Notterman DA, Ward RM, Weismann DN, Wilson GS, Wilson JT (American Academy of Pediatrics Committee on Drugs): Neonatal drug withdrawal. Pediatrics 101:1079-1088, 1998.
11. Berlin, CM, McCarver, DG, Notterman, DA, Ward, Weismann, DB, Wilson, GS, Wilson, JT ADrugs for Pediatric Emergencies@, (Committee on Drugs), Pediatrics 101(1):3, 1998.
12. Berlin CM, McCarver DG, Notterman DA, Ward RM, Weismann, DN, Wilson GS, Wilson JT, APrevention of medication errors in the pediatric inpatient setting.@ (American Academy of Pediatrics Committee on Drugs), Pediatrics 102: 428-430, 1998.
13. Lemons JA, Blackmon LR, Kanto WP, MacDonald HM, Miller CA, Papile LA, Rosenfeld W, Shoemaker CT, Speer, ME (Committee on Fetus and Newborn), Ward RM, Bates BA, McCarver DG, Notternman DA, Walson, PD, Weisman, PD, Wilson JT (Committee on Drugs): Prevention and Management of pain and stress in the neonate. Pediatrics 105: 454-461, 2000.
Published Abstracts:
1. Csuka ME, Black C, May DG, Porter J, Branch RA: Rapid dapsone hydroxylation in systemic sclerosis: a novel hypothesis. Arthritis Rheum, 1987.
2. May DG, Ward SA, Naukam RJ, Kambam JR, Heath AJ, Branch RA: Pharmacokinetic and pharmacodynamic interaction between carbaryl and cimetidine. Vet Hum Toxicol, 30(4):363, 1988.
3. May DG, Black C, Olsen N, Osuka M-E, Tanner B, Wilkinson GR, Branch RA: Metabolism of debrisoquine, mephenytoin, and dapsone in scleroderma. Eur J Clin Pharmacol, 36:A61, 1989.
4. May DG, Arns PA, Richards WO, Ryder D, Porter J, Wilkinson GR, Branch RA: Preservation of dapsone clearance in patients with cirrhosis. Clin Res, 38:419A, 1990.
5. Fleming C, May DG, Arns P, Wilkinson GR, Guengerich FP, Branch RA: Cytochrome P450IIIA-mediated hydroxylation of dapsone in normal subjects and cirrhotics. J Hepatol, 11(suppl 2):S87, 1990.
6. Yates RA, Bluhm R, Branch R, Werth S, King L, Gross A, May G: Dapsone metabolism in the treatment of inflammatory dermatoses. South Med J, 83:2S-14, 1990.
7. Bluhm R, Yates R, King L, Werth S, Gross A, May G, Branch RA: Dapsone toxicity and its relationship to N-hydroxylation and acetylation. Clin Pharmacol Ther, 49:157, 1991.
8. May DG, Durisin L, Sokol R: Accurate, sensitive, automated GC assay for simultaneous measurement of ethanol (ETOH) and acetaldehyde (AA) in humans in vivo. Alcohol Clin Exp Res, 15:378, 1991.
9. May DG, Thomasson HR, Martier S, Ager J, Durisin L, Mowery J, Reasonover L, Sokol R, Li T-K: Ethanol metabolism in women: relative importance of ADH genotype and intake. Alcohol Alcohol, 27(Suppl 1):41, 1992. Also published in Alcohol Clin Exp Res, 16(3):605, 1992.
10. Elton R, May DG, Kauffman R, Towbin R: Efficacy and toxicity of sedatives in pediatric patients undergoing CT scan. Clin Res, 40(3):706A, 1992.
11. May DG, Durisin L: Human ß1ß1 and ß3ß3 alcohol dehydrogenase isoenzymes do not metabolize the cytochrome P4502E1 substrate, chlorzoxazone. Alcohol Clin Exp Res, 17:496, 1993.
12. May DG, Thomasson HR, Martier SS, Mowery JL, Durisin L, Barker K, Sokol RJ, Li T-K: ADH2 genotype and minimal drinking impact the apparent ethanol kinetic parameters of African American women. Alcohol Clin Exp Res, 17:494, 1993.
13. May DG, Thomasson HR, Martier SS, Mowery JL, Durisin L, Barker KL, Sokol RJ, Li T-K: Determinants of intersubject variation in maternal alcohol metabolism: a role in susceptibility to alcohol related birth defects? Pediatr Res, 33(4):73A, 1993.
14. Kang JH, Aouthmany M, Elton RM, Slovis TL, Kauffman, RE, McCarver-May DG: Efficacy, toxicity and pharmacokinetics of chloral hydrate (CH) and midazolam (MZ) in post-ECMO neonates. Pediatr Res 35:77A, 1995.
15. McCarver-May DG, Durisin L: Variation in chlorzoxazone (CZ) metabolism in African American women. Alcohol Clin Exp Res 19(2):76A, 1995.
16. Mowery JL, Robinson TR, Martier SS, Sokol RL, McCarver-May DG: Knowledge and misconceptions in inner city African American women regarding alcohol and drug use. Alcohol Clin Exp Res 19(2):94A, 1995.
17. Seagull FN, Simpson PM, Mowery JL, Robinson TR, Martier SS, Sokol RJ, McCarver-May DG: Maternal assessment of infant development: associations with alcohol and drug use in pregnancy. Alcohol Clin Exp Res 19(2):104A, 1995.
18. McCarver-May DG, Elton RM, Kang J, Aouthmany M: Chloral hydrate (CH) and cancer: studies of CH disposition in human infants and adults. Clin Pharmacol Ther 59(2): 144, 1996.
19. Byun R, Durisin L, Mowery JL, McCarver-May DG: Factors influencing the 40 fold variation in CYP2E1 metabolic ability in African American women. Clin Pharmacol Ther 59(2):134, 1996.
20. Rasheed A, Hines RN, McCarver-May DG: Variation in induction of placental cytochrome P4502E1: possible role in susceptibility to fetal alcohol syndrome? Pediatr Res 39(4):83A, 1996.
21. McCarver-May DG, Thomasson H, Martier SS, Sokol R, Li T-K: Alcohol dehydrogenase2*3 allele protects against adverse developmental offspring outcome after intrauterine alcohol exposure. Alcohol Clin Exp Res 20(2):122A, 1996.
22. McCarver-May DG: Genetic differences in alcohol dehydrogenase and fetal alcohol effects. Braz J Genetics 19(2):73, 1996.
23. McCarver-May DG, Durisin L: Chlorzoxazone may be useful to alcohol researchers as a specific probe of cytochrome P4502E1. Alcohol Res 1(3/4):105, 1996.
24. McCarver DG, Thomasson HR, Martier SS, Sokol RS, Li T-K: Alcohol dehydrogenase: genes, ethanol (ETOH) metabolism and intrauterine ETOH exposure risk. Fundam Appl Toxicol 36(1):333-4, 1997.
25. Dalere M, Shankaran S, Woestenborghs R, McCarver-May DG: Altered cisapride absorption in preterm infants with gastroesophageal reflux: implications for efficacy? Pediatr Res 41(4):55A, 1997.
26. McCarver DG, Thomasson HR, Li T-K: Variation in CYP2E1 as a determinant of ethanol metabolism in postpartum African American women. Alcohol Clin Exp Res, 21(5):51A, 1997.
27. Rasheed A, Hines RN, McCarver DG: Variation in human placental CYP2E1: potential risk factor for growth retardation associated with intrauterine alcohol exposure. Alcohol Clin Exp Res, 21(5):53A, 1997.
28. Simpson PM, McCarver DG, Twehues LE, Hamer R: Since when does correlation imply valid substitution? Controlled Clin Trials, 18(3S):174S, 1997.
29. McCarver DG: Genetic susceptibility to alcohol related birth defects. Alcohol Clin Exp Res, 22:153A, 1998.
30. McCarver DG, Hines RN, Byun, Hichme, M: CYP2E1 Mutation associated with increased chlorzoxazone metabolic ability. Toxicol Lett, Supplement 1/95:98 (Abstract P2A22), 1998.
31. Hines, RN, Luo Z, Whetsine J, Yueh MF, McCarver DG, Williams DE: Regulation of the flavin-containing monooxygenases (FMOs): tissue- and species-specificity. Exp Toxicol Pathol 50 (2): 108, 1998.